HIV, Allergies, and Cardiovascular Health: A Complex Interplay

For individuals living with Human Immunodeficiency Virus (HIV), the challenges extend beyond managing the virus itself. Emerging research highlights a complex relationship between HIV, immune system dysregulation leading to increased allergic sensitivities, and a heightened risk of cardiovascular disease (CVD). This article explores these interconnected health concerns, providing an overview of current understanding and potential avenues for improved patient care.

The Immune System and HIV: A Delicate Balance

HIV directly attacks the central control mechanisms of the immune response, ultimately leading to opportunistic infections and malignancies if left untreated. However, even before significant immunodeficiency develops, many people with HIV experience immune-based hypersensitivity diseases. Research indicates that this hypersensitivity often manifests as IgE-mediated conditions, commonly known as allergies.

Allergies in People Living with HIV

The incidence of allergies (atopy) in people with HIV is generally similar to that of the general population, with one notable exception: drug sensitivities. Individuals with HIV are significantly more likely to experience allergic reactions to medications. Studies show that clinical manifestations of allergies are comparable between the two groups, and the standard therapeutic approach remains the same. Allergen immunotherapy (AIT), a treatment to desensitize individuals to specific allergens, is currently being investigated for use in people with HIV, with early data suggesting it may be safe and effective, particularly in those with early or middle-stage disease.

HIV and Cardiovascular Disease: A Growing Concern

Beyond allergies, HIV infection is increasingly recognized as a significant risk factor for cardiovascular disease. Prevalence studies show a wide range of moderate to severe coronary disease (0% to 52%) and myocardial fibrosis (5% to 84%) among people living with HIV. This increased risk is largely attributed to persistent inflammation caused by the virus, even in individuals receiving antiretroviral therapy.

The Role of Inflammation

HIV infection triggers systemic inflammation that extends beyond the depletion of CD4+ T cells. Research demonstrates that innate immune cells, such as monocytes, play a crucial role in driving this inflammation. Specifically, studies focusing on women with HIV have revealed altered gene expression in circulating monocytes, even in those with well-controlled viral loads and subclinical CVD. These changes suggest monocytes may serve as potential viral reservoirs and contribute to the development of cardiovascular complications.

Monocyte Subtypes and CVD

Further investigation into monocyte subtypes – non-classical monocytes (NCM) and intermediate monocytes (IM) – has revealed distinct patterns of gene expression in people with HIV. Even as IM gene expression is relatively unaffected by HIV or CVD alone, the coexistence of both conditions triggers a unique transcriptional signature. This signature can be mitigated by lipid-lowering treatments. NCM, exhibit altered gene expression in people with HIV regardless of CVD status, with the most significant changes observed in those with both HIV and CVD. Upregulated genes, such as LAG3 (CD223), represent potential targets for therapeutic intervention.

Looking Ahead

The interplay between HIV, allergies, and cardiovascular disease is complex and requires ongoing research. As life expectancies for people with HIV continue to improve with advancements in antiretroviral therapy, addressing these interconnected health concerns becomes increasingly important. Further studies are needed to optimize management strategies, minimize morbidities, and enhance the quality of life for individuals living with HIV. The practicing allergist-immunologist and cardiologist should be aware of these associations and prepared to provide comprehensive care to this growing population.